Journal of Aging Science

Thrifty Hormone Ghrelin: The Secret of Aging Muscularly

Yuxiang Sun^* Department of Nutrition, Texas A&M University, College Station, Texas, USA
^*Correspondence: Yuxiang Sun, Department of Nutrition, Texas A&M University, College Station, Texas, USA, Tel: 979-862-9143, Email:

Received: 19-Dec-2020 Published: 31-Dec-2020, DOI: 10.35248/2329-8847.20.S3.005

Introduction

Sarcopenia is a degenerative loss of skeletal muscle mass which seriously affects the independence and quality-of-life of the elderly [1,2]. The major characteristic of sarcopenia is skeletal muscle atrophy, which involves massive loss of muscle structural proteins, leading to decreased muscle mass and progressive decline of muscle function. Skeletal muscle atrophy can be triggered by aging, inactivity, malnutrition, inflammation and/or denervation. Elderly are prone to muscle loss, and sarcopeniaassociated disability is a huge challenge for aging care. Given the rising aging population worldwide, it is critically important to identify preventive and therapeutic strategies to combat muscle loss during aging. Exercise is known to mitigate muscle sarcopenia by improving muscle mass and function [2,3], but most frail elderly are not physically capable of exercise, which makes muscle-boosting interventions such as exercise unsuitable for the elderly. Currently, there is no effective therapy for sarcopenia in aging.

The pathogenesis of sarcopenia is a complex one, with various metabolic mediators affecting muscle fiber size, mitochondrial function, and apoptosis of myocytes. Since Growth Hormone (GH) is known to promote muscle growth and differentiation through the GH/insulin-like growth factor (IGF) axis, gut hormone ghrelin and ghrelin mimetics have emerged as attractive potential candidates for treating sarcopenia [4]. This review will discuss the promising role of ghrelin-related peptides in muscle atrophy.

Literature Review

Ghrelin-related peptides and ghrelin receptor

Ghrelin, a 28-amino acid peptide hormone produced mainly by the stomach, has multi-faceted roles such as nutritional regulation, metabolism, and inflammation [5-9]. Classically known as the “hunger hormone,” ghrelin stimulates food intake, induces GH secretion, and promotes adiposity through its receptor, the growth hormone secretagogue receptor (GHS-R) [10,11]. Ghrelin, as a nutrient sensor, it is increased by fasting and is suppressed by feeding [12-14]. While the phenotypic impact of ghrelin deficiency in mice is very mild under hemostatic condition, its effects are much more pronounced under energy deficit. We showed that ghrelin-null mice have reduced blood glucose under 50% calorie restriction, and ghrelin ablation ameliorates the hyperglycemic phenotype of leptin-deficit ob/ob mice [15-17]. The octanoylation of ghrelin is mediated by Ghrelin O-acyltransferase (GOAT) [18,19]. Strikingly, GOAT-null mice die of hypoglycemia under 60% severe calorie restriction due to dysfunction of a GH-mediated survival mechanism [20]. Therefore, ghrelin gene is considered as “thrifty” gene because it is evolutionally conserved to help animals store energy, in order to increase their chances of survival in times of famine [21].

Acylated ghrelin and unacylated ghrelin-two sides of the same coin

Two peptides are derived from the preproghrelin gene: Acylated Ghrelin (AG) is with a unique post-translational octanoylation on Ser3 by GOAT, and Unacylated Ghrelin (UAG) is without the octanoylation modification [19]. Octanoylation on Ser3 is required for binding to the receptor GHS-R, so AG activates GHS-R, while UAG does not [18]. Thus, originally it was thought that only AG has biological functions, so AG has often been simply referred as ghrelin; meanwhile, UAG is called inactive ghrelin. Later, a number of lines of evidences have shown that UAG has biological functions as well, despite the receptor of UAG is unknown. UAG modulates lipogenic and insulin-signaling pathways in metabolically active tissues such as fat, muscle, and liver in the absence of GHS-R [22]. Also UAG has been shown to be increased after aerobic exercise [23,24], and it counteracts the metabolic response of AG, but not the neuroendocrine response of AG [25]. Even though AG and UAG are derived from the same gene, UAG is far more abundant in plasma than AG; the concentration of UAG in the circulation is more than 90%, while UAG is only 5%-10%, because AG needs to undergo additional octanoylation modification by GOAT [19]. A recent report further reveals that the ratio of AG: UAG has important biological implication in neurodegenerative diseases [26].

Major signaling pathways in muscle metabolism and function

Sarcopenia involves muscle atrophy and mitochondrial dysfunction. Exercise has been shown to improve muscle health by improving muscle mass and function [2,3]. Exercise increases insulin-signaling regulator AKT, mammalian Target of Rapamycin complex (mTOR), sirtuin family member SIRT3, and peroxisome-proliferator-activated receptor-g coactivator-1a (PGC-1a). The mTOR signaling has a key regulatory role in muscle cell growth, and is a critical sensor of nutritional status [27]. Exercise has been shown to attenuate age-related decline of muscle protein synthesis by activating AKT-mTOR signaling [28]. SIRT3, a member of the sirtuin family of protein deacetylases, is located in mitochondria and regulates mitochondrial function [29]. PGC-1a plays a central role in mitochondrial biogenesis [30], and exercise induces mitochondrial biogenesis by increasing PGC-1a expression and deacetylation [31,32]. It has been shown that exercise regulates SIRT3 in muscle to activate PGC-1a [33]. Adenosine Monophosphate-Activated Protein Kinase (AMPK) is a major metabolic regulator of muscle metabolism, AMPK-mediated muscle autophagy is important in maintaining integrity and mitochondrial function of muscle during prolonged fasting and myopathy in aging [34]. Since ghrelin is a potent GH secretagogue, it is considered as a candidate for treatment of sarcopenia [35]. It would be interesting to determine whether ghrelin signaling regulates these metabolic and mitochondrial pathways to elicit protective effects on muscle.

Role of AG and UAG in myocytes

In vitro, it is shown that AG and UAG promote differentiation and fusion of C2C12 cells in the absence of GHS-R [36]. Interestingly, UAG exhibits both pro-anabolic and anti-anabolic effects on C2C12 myotubes exposed to cytokines [37]. More excitingly, our collaborator’s team has reported that: 1) AG and UAG act on a common, unidentified receptor to block skeletal muscle atrophy independent of GHS-R and GH/IGF-1; 2) AG and UAG inhibit skeletal muscle atrophy through PI3Kß, mTORC2, and inflammatory p38 signal pathways 3) UAG has a protective effect on muscle atrophy in mice: Pharmacological administration of UAG ameliorates skeletal muscle atrophy induced by prolonged fasting or denervation [38].

Although exercise is proven to be beneficial for sarcopenia, increasing muscle anabolism by modulating metabolic regulators of AKT and mTOR, and mitochondrial regulators of SIRT3, AMPK and PGC-1a [33,39], the reality is that exercise is challenging for old people and may even be dangerous for frail elderly who suffer sarcopenia. It is exciting to see AG and UAG enhancing muscle health by regulating these signaling pathways of PI3K and mTORC2 in muscle [38], normally activated by exercise, without changing physical activity levels.

Ghrelin gene in muscle atrophy in aging

We recently reported that old mice deficient in ghrelin are more susceptible to fasting-induced muscle atrophy, and that AG and UAG can reverse the process by promoting anabolic effects and suppressing catabolic muscle metabolism [40]. Fasting-induced muscle loss was exacerbated in old ghrelin-null mice, showing decreased expression of myogenic regulator MyoD and increased expression of protein degradation marker MuRF1, as well as altered mitochondrial function. Remarkably, AG and UAG treatments effectively increased myogenic genes and decreased degradation genes in the muscle of fasted old ghrelin-null mice [40]. We have also found that AG and UAG increase expression of Insulin Receptor Substrates (IRS1 and IRS2) and enhance activity of AMPK, and the regulating effect of UAG on these regulatory genes appears to be even more robust. Moreover, we found that AG and UAG treatments significantly increased the mitochondrial respiratory capacity of muscle C2C12 cells, which is in agreement with the protective effect observed in vivo. Our data together indicate that UAG ameliorates sarcopenia by activating anabolic genes and suppressing catabolic genes to increase muscle mass, and by modulating metabolic signals and mitochondrial machinery to improve muscle function [40]. Collectively, our results suggest that AG and UAG have major roles in the maintenance of aging muscle, enhancing muscle anabolism and exerting protective effects against muscle loss. AG and UAG may hold exciting promise for prevention/ treatment of sarcopenia in aging.

The therapeutic advantage of UAG in muscle

While AG has anti-atrophic effect on muscle, being a GH secretagogue and possessing orexigenic and obesogenic properties, AG also activates GH and increases obesity at the same time. In contrast, UAG possesses similar anti-atrophic effects on muscle as AG, but it doesn’t stimulate GH release nor promote obesity. High GH has been shown to potentially increase risk for cancers [41]. Since UAG does not activate GHSR, UAG has beneficial effects on muscle but avoids the cancer and obesity risks associated with AG. In our study, it appears that UAG is more potent in regulating myogenic, insulinsignaling, and AMPK genes [40]. UAG is an effective agent protecting against muscle wasting without undesirable sideeffects, which this makes it a superior therapeutic option for the prevention/treatment of muscle atrophy.

The biological effects and therapeutic implications of UAG have revealed great promise and warrant further investigation. Studies of chronological changes of UAG throughout lifespan, identification of a UAG receptor, and better understanding of the molecular mechanisms that mediate the effects of UAG in muscle will provide further insights to the understanding of UAG in pathogenesis of sarcopenia, and advance the development of therapeutic application of UAG in sarcopenia.

Discussion

In summary, this review has illustrated both in vivo and in vitro evidences that ghrelin-related peptides AG and UAG have crucial roles in preserving muscle mass and improving muscle function (Figure 1).

Figure 1: Schematic illustration of the rejuvenating effect of ghrelin-related peptides in atrophic aging muscle. AG and UAG protect against muscle atrophy in aging mice by up-regulating anabolic myogenic genes and down-regulating catabolic degradation genes. The inserted data figure is from our publication in Journal of Gerontology (2020) 75:621-630.

These exciting findings suggest that ghrelin signaling has important and unique roles in maintenance of muscle health, hold great potential to be anti-sarcopenia therapy. AG and UAG trigger anti-atrophic signaling pathways directly in myocytes to protect against muscle atrophy, independent of ghrelin receptor GHS-R and the classical nourishing mechanism of GH/IGF-1 activation.

Conclusion

AD and UAG rejuvenate muscle without requiring physical activity, which could have tremendous benefits for frail elderly who cannot exercise. AG and UAG function as exercise mimetics to protect and nourish muscle without exercise, thus ameliorating muscle atrophy and rejuvenating aging muscle by activating exercise-like signaling pathways in muscle, offering an excellent anti-sarcopenia candidate for the elderly.

Lastly, UAG has impressive anti-atrophic effect in muscle, it increases muscle mass and improves muscle function. It is remarkable that UAG has the muscle-nourishing effects as AG, but is devoid of the potential carcinogenic and obesogenic side effects associated with AG. Thus, UAG represents a unique and more attractive therapeutic option for muscle-wasting diseases such as sarcopenia in aging. It would be beneficial to identify the receptor for UAG, and further elucidate the detailed signaling cascades mediating the effects of UAG in myocytes under normal and atrophic conditions.

Acknowledgement

This work of the author is supported by National Institutes of Health (NIH) R01DK118334 and R01AG064869, Alzheimer’s Disease Research Grant A2019630S from Bright Focus Foundation. The author is also very grateful to Mr. Michael R. Honig at Houston’s Community Public Radio Station KPFT for his excellent editorial assistance, and Kevin T Jones for his insightful comments.

REFERENCES

1. Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int J Endocrinol. 2012;2012: 127362.
2. Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010;11(4): 1509-1526.
3. Lanza IR, Nair KS. Muscle mitochondrial changes with aging and exercise. Am J Clin Nutr. 2009;89(1): 467S-4671S.
4. Ali S, Garcia JM. Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options: A mini-review. Gerontology. 2014;60(4): 294-305.
5. Kojima M, Kangawa K. Structure and function of ghrelin. Results Probl Cell Differ. 2008;46: 89-115.
6. Pradhan G, Samson SL, Sun Y. Ghrelin: Much more than a hunger hormone. Curr Opin Clin Nutr Metab Care. 2013;16(6): 619-624.
7. Smith RG, Jiang H, Sun Y. Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol Metab. 2005;16(9): 436-442.
8. Sun Y, Asnicar M, Smith RG. Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology. 2007;86(3): 215-228.
9. Muller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. 2015;4(6): 437-460.
10. Kojima M, Kangawa K. Ghrelin: Structure and function. Physiol Rev. 2005;85(2): 495-522.
11. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA. 2004;101(13): 4679-4684.
12. Kim MS, Yoon CY, Park KH, Shin CS, Park KS, Kim SY, et al. Changes in ghrelin and ghrelin receptor expression according to feeding status. Neuroreport. 2003;14(10): 1317-1320.
13. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, et al. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun. 2001;281(5): 1220-1225.
14. Tilston TW, Brown RD, Wateridge MJ, Arms-Williams B, Walker JJ, Sun Y, et al. A Novel automated system yields reproducible temporal feeding patterns in laboratory rodents. J Nutr. 2019;149(9): 1674-1684.
15. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol. 2003;23(22): 7973-7981.
16. Sun Y, Asnicar M, Saha PK, Chan L, Smith RG. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 2006;3(5): 379-386.
17. Sun Y, Butte NF, Garcia JM, Smith RG. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology. 2008;149(2): 843-850.
18. Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev. 2009;61(4): 430-481.
19. Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A. 2008;105(17):6320-6325.
20. Zhao TJ, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(16): 7467-7472.
21. Cummings DE, Foster-Schubert KE, Overduin J. Ghrelin and energy balance: Focus on current controversies. Curr Drug Targets. 2005;6(2): 153-169.
22. Delhanty PJ, Sun Y, Visser JA, van Kerkwijk A, Huisman M, van Ijcken WF, et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One. 2010;5(7): e11749.
23. Bahman M, Khadije I, Farhad R-N, Hamid M, Sadegh H-N. Unacylated ghrelin levels increase after aerobic exercise program in obese women. Brazil J Biomotri. 2009;3(1): 10.
24. Foster-Schubert KE, McTiernan A, Frayo RS, Schwartz RS, Rajan KB, Yasui Y, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab. 2005;90(2):820-825.
25. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab. 2004;89(6):3062-3065.
26. Hornsby AKE, Buntwal L, Carisi MC, Santos VV, Johnston F, Roberts LD, et al. Unacylated-ghrelin impairs hippocampal neurogenesis and memory in mice and is altered in parkinson's dementia in humans. Cell Rep Med. 2020;1(7): 100120.
27. D'Antona G, Nisoli E. mTOR signaling as a target of amino acid treatment of the age-related sarcopenia. Int Top Gerontol. 2010;37: 115-141.
28. Reynolds TH, Reid P, Larkin LM, Dengel DR. Effects of aerobic exercise training on the protein kinase B (PKB)/mammalian target of rapamycin (mTOR) signaling pathway in aged skeletal muscle. Exp Gerontol. 2004;39(3): 379-385.
29. Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol. 2002;158(4): 647-657.
30. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1 alpha. Cardiovasc Res. 2008;79(2): 208-217.
31. Taylor EB, Lamb JD, Hurst RW, Chesser DG, Ellingson WJ, Greenwood LJ, et al. Endurance training increases skeletal muscle LKB1 and PGC-1 alpha protein abundance: Effects of time and intensity. Am J Physiol Endocrinol Metab. 2005;289(6):E960-E968.
32. Li L, Pan R, Li R, Niemann B, Aurich AC, Chen Y, et al. Mitochondrial biogenesis and peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) deacetylation by physical activity: Intact adipocytokine signaling is required. Diabetes. 2011;60(1): 157-167.
33. Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y, Ward JL, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1 alpha in skeletal muscle. Aging (Albany NY). 2009;1(9): 771-783.
34. Bujak AL, Crane JD, Lally JS, Ford RJ, Kang SJ, Rebalka IA, et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab. 2015;21(6): 883-890.
35. Muller TD, Perez-Tilve D, Tong J, Pfluger PT, Tschop MH. Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2010;1(2): 159-167.
36. Filigheddu N, Gnocchi VF, Coscia M, Cappelli M, Porporato PE, Taulli R, et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell. 2007;18(3): 986-994.
37. Sheriff S, Kadeer N, Joshi R, Friend LA, James JH, Balasubramaniam A. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol Cell Endocrinol. 2012;351(2): 286-295.
38. Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest. 2013;123(2): 611-622.
39. Zhou M, Lin BZ, Coughlin S, Vallega G, Pilch PF. UCP-3 expression in skeletal muscle: effects of exercise, hypoxia, and AMP-activated protein kinase. Am J Physiol Endocrinol Metab. 2000;279(3): E622-E629.
40. Wu CS, Wei Q, Wang H, Kim DM, Balderas M, Wu G, et al. Protective effects of ghrelin on fasting-induced muscle atrophy in aging mice. J Gerontol A Biol Sci Med Sci. 2020;75(4): 621-630.
41. Swerdlow AJ, Cooke R, Beckers D, Borgström B, Butler G, Carel J-C, et al. Cancer risks in patients treated with growth hormone in childhood: The SAGhE European cohort study. J Clin Endocrinol Metab. 2017;102(5): 1661-1672.